Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy

Affiliations

¹ Division of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
² Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
³ Pediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, MD.
⁴ Division of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA.
⁵ Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
⁶ Division of Pediatric Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
⁷ Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA.
⁸ Pediatric Hematology/Oncology/BMT-CT, University of Colorado, Children's Hospital Colorado, Aurora, CO.
⁹ Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; and.
¹⁰ Division of Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT.

Emily M Hsieh et al. Blood Adv. 2022.

. 2022 Sep 13;6(17):5222-5226.

doi: 10.1182/bloodadvances.2022008093.

¹ Division of Hematology/Oncology/Transplantation and Cellular Therapy, Children's Hospital Los Angeles Cancer and Blood Disease Institute, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA.
² Division of Oncology, Cell Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA.
³ Pediatric Oncology Branch, National Cancer Institute/Center for Cancer Research, National Institutes of Health, Bethesda, MD.
⁴ Division of Hematology/Oncology, University of Washington, Seattle Children's Hospital, Seattle, WA.
⁵ Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
⁶ Division of Pediatric Hematology/Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
⁷ Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA.
⁸ Pediatric Hematology/Oncology/BMT-CT, University of Colorado, Children's Hospital Colorado, Aurora, CO.
⁹ Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; and.
¹⁰ Division of Hematology and Oncology, Intermountain Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT.

No abstract available

Figures

1. Friedman DL, Whitton J, Leisenring W, et al. . Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102(14):1083-1095. - PMC - PubMed
1. Meadows AT, Friedman DL, Neglia JP, et al. . Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27(14):2356-2362. - PMC - PubMed
1. Inamoto Y, Shah NN, Savani BN, et al. . Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015;50(8):1013-1023. - PMC - PubMed
1. Cullinan N, Schiller I, Di Giuseppe G, et al. . Utility of a cancer predisposition screening tool for predicting subsequent malignant neoplasms in childhood cancer survivors. J Clin Oncol. 2021; 39(29):3207-3216. - PubMed
1. Turcotte LM, Neglia JP, Reulen RC, et al. . Risk, risk factors, and surveillance of subsequent malignant neoplasms in survivors of childhood cancer: a review. J Clin Oncol. 2018;36(21):2145-2152. - PMC - PubMed